SCHEMBL5133261

SCHEMBL5133261

CCCCC(CC)CNC(=O)c1cc(-c2csc(C(=O)OCC)n2)n(CC2CCCO2)c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.38
TSHR P16473 2/20 0.38
TP53 P04637 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RAB9A P51151 5/20 0.37
NPC1 O15118 4/20 0.37
TDP1 Q9NUW8 3/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
EPHX2 P34913 1/20 0.36
FEN1 P39748 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
ALOX15 P16050 1/20 0.36
RECQL P46063 1/20 0.36
BLM P54132 1/20 0.36
HPGD P15428 3/20 0.35
POLB P06746 2/20 0.35
LMNA P02545 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
ADORA2A P29274 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5046957 0.90 ALDH1A1 (0.41) ALDH1A1TSHRTP53SMN1; SMN2RAB9A
SCHEMBL5043780 0.89 CTSK (0.40) TSHRTP53SMN1; SMN2TDP1L3MBTL1
SCHEMBL5045868 0.86 TSHR (0.39) ALDH1A1TSHRTP53SMN1; SMN2TDP1
SCHEMBL5039361 0.84 TSHR (0.38) ALDH1A1TSHRTP53SMN1; SMN2L3MBTL1
SCHEMBL5045678 0.84 ALDH1A1 (0.41) ALDH1A1TSHRTP53SMN1; SMN2RAB9A
SCHEMBL5043762 0.83 ALDH1A1 (0.43) ALDH1A1TSHRTP53SMN1; SMN2L3MBTL1
SCHEMBL5039350 0.80 HPGD (0.45) ALDH1A1TSHRTP53SMN1; SMN2RAB9A
SCHEMBL5133265 0.79 ALDH1A1 (0.41) ALDH1A1TSHRTP53SMN1; SMN2RAB9A
SCHEMBL5045675 0.77 ALDH1A1 (0.42) ALDH1A1TSHRTP53SMN1; SMN2RAB9A
SCHEMBL5048540 0.75 ALDH1A1 (0.48) ALDH1A1TSHRSMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R ALDH1A1 959/4885TSHR 98/4885TP53 4443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.